Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)

• Published in: Expert opinion on therapeutic patents Vol. 30; no. 4; p. 263
• Main Authors: Zhao, Chunlong, Dong, Hang, Xu, Qifu, Zhang, Yingjie
• Format: Journal Article
• Language: English
• Published: England 02.04.2020
• Subjects: inhibitors; cancer; hybrids; Histone deacetylases
• ISSN: 1744-7674
• DOI: 10.1080/13543776.2020.1725470

: Histone deacetylase (HDAC) inhibitors play a crucial role in restoring the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, which are applied to treat several diseases including cancer. : This review covers recent efforts in the synthesis and applications of inhibitors and hybrid inhibitors targeting HDAC from 2017 to 2019. : HDACs are important epigenetic targets and HDAC inhibitors have become important biologically active compounds for the treatment of cancers. Among the recent patents available, most of them place emphasis on HDAC selective inhibitors and multitarget HDAC inhibitors. Although great accomplishments have been achieved in developing HDAC selective inhibitors, there is still an urgent need for discovery of novel HDAC inhibitors with new zinc-binding groups avoiding the unfavorable pharmacokinetics profiles of hydroxamic acid. Apart from cancer therapy, HDAC inhibitors have recently been considered as a new strategy in treating other human diseases, such as alcohol use disorder (AUD), neurological disorders, age-related diseases, and so forth.